Updates
** Shares of drugmaker Soleno Therapeutics SLNO.O rise 6.4% to $49.27, its highest in nearly a month
** Soleno enters into an agreement with Jefferies LLC to repurchase $100 million of Soleno's common stock
** Co says it will make an initial payment of $100 million and receive about 1.5 million shares at first, based on Monday's closing price of $46.31/shr
** Final number of shares will be subject to adjustments related to the terms of the buyback deal
** "These actions demonstrate our confidence in our commercial launch and the compelling opportunity for VYKAT XR to become a foundational therapy for patients with hyperphagia associated with Prader Willi syndrome," says CEO Anish Bhatnagar
** The repurchase is expected to complete in Q1 2026
** 9 of 12 brokerages rate the stock "buy" or higher, and 3 at "hold"; their median PT is $112.50 – data compiled by LSEG
** Including session's move, stock up ~10% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))